OmniAb Investor Presentation Deck

Growth of Partner Programs PROGRESSION AND PERFORMANCE IN PROGRAMS BY STAGE OF DEVELOPMENT 21 as of 2016(¹) Preclinical: 1 Discovery: 20 (1) Estimated at the time of acquisition of OMT, Inc. Phase 1: 20 Preclinical: 14 301 Active Programs as of 03/31/2023 Substantial progress in all phases, increase in discovery programs expected to feed growth in new clinical programs and future approvals Phase 2: 2 Phase 3: 2 Approved: 3 Discovery: 260 6 OmniAb

View entire presentation